PurpleLab

PurpleLab announces Series B funding round led by Primus Capital Funds (Primus Capital), joining existing investor Edison Partners. The investment highlights PurpleLab’s growing role in simplifying the access to and interpretation of Real-World Data across the healthcare continuum. https://bit.ly/3RJrYio #RWD

We're excited to have played a key role in a groundbreaking cookieless advertising test conducted by Viant Technology and Havas Media Network. Our collaboration marks a significant milestone in digital advertising as the conversation around cookies continues to make headlines. Viant & Havas’ test, performed for a major US pharma company advertiser, achieved 100% scale and 93% unique reach across premium publishers while using Viant’s Household ID to target consumers instead of traditional cookies. We're proud to support this approach with insights from our extensive medical and pharmaceutical claims database at a moment when advertisers are shying away from using cookies in upcoming campaigns. Read more about the partnership below! 👇 #DigitalAdvertising #CookielessFuture #PurpleLab

Celebrity endorsements for drugs ranging from GLP-1s to migraine medications have become commonplace. However, influence isn't limited to celebrities alone. A staple piece during commercial breaks on national TV, advertising for certain drugs and treatment options has transcended traditional media. Now, we see an increase in brands teaming up with social media influencers, offering a closer and more personal way to interact with their target audience. Isabelle Cohen, Solution Engineer for #Advertising at PurpleLab joins Larry Dobrow from MM M to discuss the booming influencer marketing industry and how this has woven into the healthcare industry, while also sharing actionable insights to help healthcare advertisers maintain a competitive edge. #PharmaMarketing #HealthcareMarketing #InfluencerMarketing #PatientEngagement #Advertising #GLP1s

#Clinicaltrials require meticulous pre-planning and feasibility assessments that can delay the start date of trials. How can we expedite the process? In this first part of our Clinical Pharma series, we dive into the use of real-world evidence (RWE) to enhance clinical pharma insights and help speed up these time-consuming tasks. RWE, sourced from electronic health records (EHRs) and claims data, offers a promising solution to help accelerate the timeline by: ✅ Estimating target patient populations to determine if enough patients can be recruited within a reasonable timeframe. ✅ Evaluating inclusion and exclusion criteria by analyzing existing data to ensure criteria are realistic and not overly restrictive. ✅ Optimizing study designs by informing feasible numbers of clinic visits and follow-up periods to minimize a patient’s burden. RWE provides invaluable insights into real-world patient populations, aiding various aspects of clinical trial feasibility studies. Read more here: https://lnkd.in/dvDsFHxy

We’ve partnered with Basis Technologies to continue revolutionizing #healthcare marketing and #audience segmentation. Now, you can fetch our HCP audiences on their automation platform. 🙌 We work alongside Haymarket Media Group and Throtle to deliver unparalleled precision in reaching #HCP audiences. Talk about a perfect match– PurpleLab’s vast claims data (330 million patients), Haymarket’s expertise in healthcare #advertising, and Throtle’s advanced audience identification technology, all under one roof. In a nutshell, this partnership will allow Basis clients to access:  📊 Deterministic, clinically-relevant HCP audiences based on real-world data 📏 1:1 HCP activation and measurement 🍪 Cookieless targeting options 🥷 Privacy-safe, HIPAA-compliant data practices 🔎 Clinically reviewed data, refreshed quarterly Basis customers will be able to segment HCPs by diagnoses, prescriptions, tests, procedures, and treatments, plus have the flexibility to request custom segments tailored to their unique needs. With this partnership, we are set to drive better outcomes through precision targeting and more efficient reach. 💪  Kyle Armstrong, Theodore Sweetser, Brittany Ryan

Want to create a targeted Direct-to-Consumer (DTC) and Healthcare Provider (HCP) #marketingstrategy but unsure where to start? We’ve got you covered! 😎 We break down the process into 5 simple steps: 1️⃣ How to identify your patient population by leveraging specific conditions, procedures, tests, and prescriptions aligned with your brand's indications. 2️⃣ Explore high-value providers and their affiliations to better understand your #HCP audience and develop relevant messaging strategies. 3️⃣ Analyze #prescription trends to uncover opportunities and gaps in the market for your brand. 4️⃣ Size your patient and HCP populations to make informed decisions about your marketing channels. 5️⃣ Create privacy-safe audiences and distribute them across various channels to reach your target audience effectively. Ready to elevate your marketing strategy with data-driven insights? Let us help you create smarter media plans based on the right data. 🐾 Learn more in the link below! #PurpleLab #DataDrivenMarketing

What a week in #Cannes! 🔥 Our team had an incredible time meeting with industry colleagues and discussing a range of topics. From uncovering effective strategies to streamline overwhelming #data volumes and make better decisions, to the role of big data, robust identity solutions, and cross-platform measurement in helping pharmaceutical #advertisers navigate a fragmented ecosystem and accurately assess real-world advertising outcomes. Shout out to our amazing team members who represented us in France: Halee Graham, Theodore Sweetser, Wesley Holland, Lauren Rosenberg, and Scott Vinyard. 🙏 A big thank you to our partners and friends: MM M, Haymarket Media Group, MiQ, VideoAmp, CMI Media Group, Datavant, Havas Media Network, Publicis, Louis Naimoli, Kara Giannecchini, Zakaila Cimone, Scott Ronay, Jose Ferreira, Joe Kotz, Egbavwe Pela, MBA, Erin Madorsky, Ryan Griffin, Mitch Scharf, Hannah Simpson, Mike Bregman, Claudine Patel, and Tracey O'Brien. We arrived back home with the zoomies from all the connections we made. 🐾 Can't wait to see how the industry evolves by the time we meet again next year! #PharmaAdvertising #HealthcareAnalytics

Last week in #Cannes2024, we hosted “The Brand/Data Nexus” together with MM M where we delved into the challenges of data overload for pharma brand managers. We discussed the importance of sifting through data to drive insights, optimize targeting, and unlock new opportunities. Theodore Sweetser, our VP of Advertising, highlighted the significance of tailored messaging to reach different patient groups and the necessity of making data accessible and interpretable for creative teams. Learn more about the session here in the comments below! Special thanks to our panel ✨ Mike Bregman, Chief Activation Officer at Havas Media Group Tracey O'Brien, Chief Client Officer at Publicis Health Claudine Patel, CMO at Sanofi Egbavwe Pela, MBA, Group SVP at CMI Media Group Theodore Sweetser, VP of Advertising at PurpleLab Steve Madden, Editor-in-Chief at MM M

We've been called many things: 🐕 "your new best friend in healthcare analytics"  😱 "the biggest medical and pharmaceutical claims database in the US" 🤝  "the best data partner I've ever had" but our favorite is [PurpleLab]. 

GLP-1 agonists, widely used to treat type 2 #diabetes and #obesity, are a focal point in the #healthcare industry due to their high costs and increasing popularity.     These medications can cost over $1,000 per month and require lifelong commitment, posing a significant financial burden for both patients and payers.    With the recent announcement by Blue Cross Blue Shield of Michigan to stop covering these drugs starting January 2025, questions arise about the future of GLP-1 coverage across the industry. Our data reveals critical insights:  📊  There have been 12.2M people on GLP-1 medications from 2019-2024 in the US 📈  53% of them with commercial insurance, 18% with Medicare, 11% with Medicaid 💸  56% of these patients earn less than $40,000/year    The potential shift in coverage could leave many patients, especially those in lower income brackets, facing unaffordable out-of-pocket costs, significantly impacting their health and financial stability.    How will individuals manage these costs alongside everyday expenses? What are the long-term health implications for those who might discontinue the medication?    Read more about the impact and the future of GLP-1 coverage in the link below https://lnkd.in/dnvXGasW